Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromosporine is a **broad-spectrum, non-selective inhibitor of bromodomains**, including the BET (bromodomain and extra-terminal) family. It acts through binding the acetyllysine recognition site of bromodomains, interfering with their ability to "read" epigenetic marks and thereby modulating expression of genes involved in processes such as cell proliferation, differentiation, and energy homeostasis. Bromosporine potently **reactivates latent HIV-1 from latency in cellular models**, likely by modulating CDK9 phosphorylation via Tat, and exhibits low cytotoxicity in primary T cells at relevant concentrations. It has been widely used as a chemical probe in epigenetics and cancer research[1][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromosporine.